Wellington Management Group
RPRX

Wellington Management Group’s Repros Therapeutics Inc. RPRX Stock Holding History

Wellington Management Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-50,268
Closed -$927K – 2329
2013
Q2 		$927K Buy
+50,268
New +$888K ﹤0.01% 1781

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wellington Management Group's RPRX Position: Q3 2013 in Review

Wellington Management Group sold out of Repros Therapeutics Inc. (RPRX) in Q3 2013, closing a stake of 50,268 shares — an estimated $927K sold.

Wellington Management Group first reported a position in RPRX in Q2 2013 and held it in 1 quarter. The position peaked at $927K in Q2 2013. 92 funds tracked by Wall St. Rank hold RPRX as of Q3 2013.

  • Wellington Management Group reported no remaining Repros Therapeutics Inc. position as of Q3 2013 after selling out during the quarter.
  • Wellington Management Group sold 50,268 Repros Therapeutics Inc. shares in Q3 2013, an estimated $927K.
  • Wellington Management Group first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 1 quarter.
  • Wellington Management Group's Repros Therapeutics Inc. position peaked at $927K in Q2 2013.
  • 92 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2013.

Based on Wellington Management Group's 13F filing for Q3 2013, filed 14 Nov 2013.